Physician profile
Gilberto E Ramirez
NPI 1518981448
$12,089.55
in general payments reported to CMS, 2019-2025
51 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $1,810 · 2021: $2,109 · 2022: $1,658 · 2023: $1,801 · 2024: $1,412 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915 · Education: $4.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,914.72 |
| Education | $4.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,618.75 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $1,557.28 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,035.87 | 2021-2025 | |
| Lilly USA, LLC | $829.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $703.88 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $673.49 | 2019-2024 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $541.26 | 2019-2023 | |
| Pfizer INC. | $506.13 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $376.19 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.74 | 2021-2025 | Xifaxan |
| Amgen INC. | $328.71 | 2019-2025 | Otezla, Repatha, Otezla |
| Ironwood Pharmaceuticals, INC | $314.30 | 2021-2024 | Linzess |
| Sanofi-Aventis U.S. LLC | $311.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $311.38 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $232.06 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.